WGSNasdaqServices-Health ServicesFiscal year ends December 31
GeneDx Holdings Corp.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$66.29+2.68 (+4.21%)
Close on Oct 19, 2026
- Market cap
- $1.97B
- P/E (TTM)
- –
- Dividend yield
- –
GeneDx statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Services-Health Services companies for comparison
Valuation
| Measure | GeneDx | Industry median |
|---|---|---|
| Market Cap | $1.98B | $1.11B |
| Enterprise Value | $1.94B | $1.41B |
| PS Ratio | 4.35 | 1.60 |
| PB Ratio | 8.09 | 3.03 |
| P/TBV Ratio | 19.53 | 4.99 |
Enterprise value
| Measure | GeneDx | Industry median |
|---|---|---|
| EV / Sales | 4.27 | 1.69 |
Income (trailing twelve months)
| Measure | GeneDx | Industry median |
|---|---|---|
| Revenue | $454.43M | $561.90M |
| Gross Profit | $315.24M | $173.32M |
| Operating Income | -$92.41M | -$1.81M |
| Pretax Income | -$106.30M | -$572.42K |
| Net Income | -$106.36M | -$1.16M |
| EBITDA | -$81.47M | -$20.72K |
| EPS (Diluted) | -$3.64 | -$0.02 |
Margins
| Measure | GeneDx | Industry median |
|---|---|---|
| Gross Margin | 69.4% | 33.1% |
| Operating Margin | -20.3% | -4.45% |
| Pretax Margin | -23.4% | 1.54% |
| Profit Margin | -23.4% | -2.91% |
| EBITDA Margin | -17.9% | 2.41% |
| FCF Margin | -16.7% | 3.13% |
Returns
| Measure | GeneDx | Industry median |
|---|---|---|
| Return on Equity (ROE) | -40.8% | 1.84% |
| Return on Assets (ROA) | -22.5% | -3.06% |
| Return on Invested Capital (ROIC) | -36.2% | 2.11% |
| Return on Capital Employed (ROCE) | -22.7% | -0.57% |
Growth
| Measure | GeneDx | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 25.4% | 6.92% |
| Net Income Growth (YoY) | -7664.5% | 19.6% |
| EPS Growth (YoY) | -18300.0% | 25.8% |
| FCF Growth (YoY) | -9232.3% | -6.04% |
| Revenue Growth (3Y CAGR) | 22.1% | 10.9% |
| Revenue Growth (5Y CAGR) | 19.0% | 13.2% |
Balance sheet
| Measure | GeneDx | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $132.55M | $48.71M |
| Total Debt | $96.84M | $140.00M |
| Net Cash (Debt) | $35.71M | $205.49K |
| Net Cash Per Share | $1.20 | $0.01 |
| Equity (Book Value) | $244.22M | $235.16M |
| Book Value Per Share | $8.19 | $3.48 |
| Tangible Book Value | $101.23M | $703.69K |
| Working Capital | $171.73M | $30.48M |
Financial position
| Measure | GeneDx | Industry median |
|---|---|---|
| Current Ratio | 3.30 | 1.40 |
| Quick Ratio | 2.90 | 1.02 |
| Debt / Equity | 0.40 | 0.66 |
Cash flow (trailing twelve months)
| Measure | GeneDx | Industry median |
|---|---|---|
| Operating Cash Flow | -$48.71M | $3.10M |
| Capital Expenditures | -$27.09M | -$18.62M |
| Free Cash Flow | -$75.80M | $23.73M |
| FCF Per Share | -$2.54 | $0.37 |
Efficiency
| Measure | GeneDx | Industry median |
|---|---|---|
| Asset Turnover | 0.96 | 0.87 |
| Inventory Turnover | 9.36 | 11.67 |
| Revenue Per Employee | $349.56K | $228.48K |
| Profits Per Employee | -$81.81K | -$5.75K |
| Employee Count | 1,300 | 910 |
Dividends and yields
| Measure | GeneDx | Industry median |
|---|---|---|
| Earnings Yield | -5.38% | -0.59% |
| FCF Yield | -3.83% | 1.74% |
Shares
| Measure | GeneDx | Industry median |
|---|---|---|
| Shares Outstanding | 29,822,500 | 58,282,400 |
| Shares Change (YoY) | 3.65% | 2.68% |
| Shares Change (QoQ) | 0.46% | 0.32% |
| Shares Held by Institutions | 106.9% | 85.9% |
Taxes
| Measure | GeneDx | Industry median |
|---|---|---|
| Income Tax | $62.00K | $697.00K |
Scores
| Measure | GeneDx | Industry median |
|---|---|---|
| Altman Z-Score | 1.51 | 2.05 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | -2.36 | -2.71 |
Calculated by StockData from GeneDx's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.